We identify an unexpected function of PODXL as a decoy receptor that relieves the invasion-inhibiting effect of the glycocalyx component galectin-3 (GAL3) and demonstrate that the levels of this switch identify prostate cancer patients with high metastasis and poor outcome. Here, PODXL is linked to prostate cancer.